Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 38Active not recruiting 20Not yet recruiting 18Completed 8Withdrawn 4Unknown 3Terminated 3Suspended 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Cisplatin 4130-nm albumin-bound paclitaxel 3camrelizumab 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Laparoscopy 2Bevacizumab 2trilaciclib 1trastuzumab deruxtecan 1toripalimab 1selinexor 1sacituzumab govitecan 1ribociclib 1olaparib 1nimotuzumab 1lenvatinib 1fluorodopa F 18 1durvalumab 1decitabine and cedazuridine drug combination 1dalpiciclib 1cemiplimab 1carfilzomib 1apatinib 1anlotinib 1abemaciclib 1Valacyclovir 1Temozolomide 1Taxes 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Enrolling by invitation × cemiplimab × Clear all
NCT06848088 2026-01-12

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

Regeneron Pharmaceuticals

Phase 2 Enrolling by invitation
48 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡